{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-044792","form_type":"8-K","ticker":null,"cik":"0001442836","company_name":"Mersana Therapeutics, Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.312266+00:00","generated_at":"2026-05-22T11:26:10.318369+00:00","sec_items":["2.05","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Mersana cuts workforce ~55%, eliminates internal pipeline, extends cash runway to mid-2026","bullets":["Workforce reduction of approx. 55% across functions; substantially complete by Q3 2025.","Company eliminates internal pipeline development; focuses Emi-Le (B7-H4 ADC) on breast cancer.","Estimated restructuring costs of $4-5M for severance, benefits, and outplacement.","Cash runway extended to mid-2026 through cost-saving initiatives.","Conference call on May 15 to discuss business updates and Q1 2025 financial results."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-044792","json":"https://secwatch.observer/filing/0001104659-25-044792.json","markdown":"https://secwatch.observer/filing/0001104659-25-044792.md","text":"https://secwatch.observer/filing/0001104659-25-044792.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925044792/0001104659-25-044792-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925044792/tm2514089d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T11:26:10.318369+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5e29ec4fa567af3b46fa36207fe53d9bcb8c2466","claim":"Mersana Therapeutics, Inc. announced a restructuring with charges of Restructuring costs of approximately $4-5 million in cash expenditures for severance, benefit payments, outplacement services and related expenses. affecting all functions (approximately 55% reduction of current employee base).","evidence_excerpt":"On May 6, 2025, Mersana Therapeutics, Inc. (the “Company”) announced the implementation of a strategic restructuring and reprioritization plan. In connection therewith, on May 5, 2025, the Company’s board of directors approved certain expense reduction measures, including the Company’s commitment to a reduction of approximately 55% of the Company’s current employee base across all functions (the “Restructuring”). The Restructuring is expected to be substantially complete by the end of the third quarter of 2025. As a result of the Restructuring, the Company estimates that it will incur approximately $4-5 million in costs resulting from cash expenditures consisting of severance and benefit payments, outplacement services and related expenses.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925044792/0001104659-25-044792-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"Restructuring costs of approximately $4-5 million in cash expenditures for severance, benefit payments, outplacement services and related expenses."},{"label":"Affected area","value":"all functions"},{"label":"Headcount","value":"approximately 55% reduction of current employee base"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}